Improvement in patients with comorbidities

Nasal obstruction results in comorbid asthma & AERD

Nasal obstruction symptoms bar graph
Nasal obstruction symptoms bar graph

LS means from analysis using mixed model repeated measures.

Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).

Also known as NERD.

ACQ-5 results in comorbid asthma

Improvement in asthma control in patients with comorbid asthma

ACQ-5 responder analysis*

Lungs Icon

57%

of patients

had a clinically important
difference on NUCALA vs 35%
on placebo at Week 521,2

Post hoc analysis. Results are descriptive.

NUCALA + SOC (n=138) vs placebo + SOC (n=144), OR: 2.42 (95% CI: 1.43, 4.11). 

Defined as improvement in ACQ-5 total score of ≥0.5 points from baseline for minimal clinically important difference.2,3

NUCALA is for the add-on treatment of patients 6+ with severe eosinophilic asthma. Not for acute bronchospasm or status asthmaticus.

ACQ-5=Asthma Control Questionnaire (5-item); AERD=aspirin-exacerbated respiratory disease; CI=confidence interval; LS=least squares; NERD=nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; OR=odds ratio; SOC=standard of care; VAS=visual analogue scale.